{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-001506","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.494951+00:00","generated_at":"2026-05-15T12:52:58.904748+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Filana Therapeutics reports 2025 net loss of $91M; cash burn guidance and TSC program clinical hold detailed","bullets":["Net loss $91.0M ($1.88/share) vs $24.3M ($0.53) in 2024; cash $95.5M at Dec 31, 2025.","Est. cash at June 30, 2026 at $47-50M; net cash use H1 2026 $14-17M plus $31.25M litigation settlement payment.","R&D expenses fell 62% to $26.6M after Alzheimer's program phase-out; TSC program on clinical hold since Dec 2025.","G&A expenses $68.8M include $31.3M securities litigation contingency; no insurance recoveries.","Name change to Filana Therapeutics reflects focus on filamin A modulation for TSC-related epilepsy."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-001506","json":"https://secwatch.observer/filing/0001171843-26-001506.json","markdown":"https://secwatch.observer/filing/0001171843-26-001506.md","text":"https://secwatch.observer/filing/0001171843-26-001506.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000117184326001506/0001171843-26-001506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000117184326001506/f8k_031226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T12:52:58.904748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a010b0c77d0325fb523f62a81e2019b38b529337","claim":"FILANA THERAPEUTICS, INC. reported the fourth quarter and year ended December 31, 2025 results: net income Net loss for 2025 was $91.0 million, EPS $1.88 per share.","evidence_excerpt":"Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000117184326001506/0001171843-26-001506-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2025"},{"label":"Net income","value":"Net loss for 2025 was $91.0 million"},{"label":"EPS","value":"$1.88 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}